Nanodigmbio Technology Co., Ltd

In 2020, Nanodigmbio Technology rejected the acquisition and relied on self-developed products to open up industry channels and stay at the forefront of the industry. On November 26, 2021, Nanodigmbio's new oligonucleotide manufacturing facility for high-throughput sequencing was officially opened.

The new >1500 m2 clean production workshop and laboratory, and the ISO 13485:2016 medical device quality management system are the guarantee for us to meet the needs of customers and regulatory requirements in the future. So starting from upstream raw materials, Naondigmbio Technology uses high-quality probe design and synthesis platform as the core, to support targeted sequencing products and closed-loop solutions to serve customers and service diagnosis.

Nanodigmbio Technology oligonucleotide facility is divided into five major functional areas, including office area, synthesis area, purification area, QC area, and production area. It also owns various types of synthesizers, purifiers, automatic pipetting workstations, gas-phase ammonolysis analyzers, and mass spectrometers.